DK1392307T3 - Tartratsalte af 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen - Google Patents

Tartratsalte af 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen

Info

Publication number
DK1392307T3
DK1392307T3 DK02722625T DK02722625T DK1392307T3 DK 1392307 T3 DK1392307 T3 DK 1392307T3 DK 02722625 T DK02722625 T DK 02722625T DK 02722625 T DK02722625 T DK 02722625T DK 1392307 T3 DK1392307 T3 DK 1392307T3
Authority
DK
Denmark
Prior art keywords
triazatetracyclo
pentaene
hexadeca
tartrate salts
tartrate
Prior art date
Application number
DK02722625T
Other languages
Danish (da)
English (en)
Inventor
Peter Robert Rose
Glenn Robert Williams
David Everett Bogle
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1392307(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1392307T3 publication Critical patent/DK1392307T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DK02722625T 2001-05-14 2002-04-26 Tartratsalte af 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen DK1392307T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29086101P 2001-05-14 2001-05-14

Publications (1)

Publication Number Publication Date
DK1392307T3 true DK1392307T3 (da) 2005-11-07

Family

ID=23117845

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02722625T DK1392307T3 (da) 2001-05-14 2002-04-26 Tartratsalte af 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen

Country Status (48)

Country Link
US (2) US6890927B2 (sk)
EP (1) EP1392307B1 (sk)
JP (1) JP3779682B2 (sk)
KR (1) KR100551184B1 (sk)
CN (1) CN100370987C (sk)
AP (1) AP1473A (sk)
AR (1) AR033635A1 (sk)
AT (1) ATE302607T1 (sk)
AU (1) AU2002253482B2 (sk)
BG (1) BG66408B1 (sk)
BR (1) BR0209605A (sk)
CA (1) CA2447405C (sk)
CR (1) CR7080A (sk)
CZ (1) CZ304763B6 (sk)
DE (1) DE60205742T2 (sk)
DK (1) DK1392307T3 (sk)
DO (1) DOP2002000392A (sk)
EA (1) EA005528B1 (sk)
EC (2) ECSP034849A (sk)
EE (1) EE05441B1 (sk)
EG (1) EG24228A (sk)
ES (1) ES2246396T3 (sk)
GE (1) GEP20053712B (sk)
GT (1) GT200200084A (sk)
HK (1) HK1062645A1 (sk)
HR (1) HRP20030910B1 (sk)
HU (1) HU229867B1 (sk)
IL (2) IL157933A0 (sk)
IS (1) IS2217B (sk)
MA (1) MA27020A1 (sk)
ME (1) ME00466B (sk)
MX (1) MXPA03010364A (sk)
MY (1) MY127807A (sk)
NO (1) NO326148B1 (sk)
NZ (1) NZ528210A (sk)
OA (1) OA12599A (sk)
PA (1) PA8545101A1 (sk)
PE (1) PE20021065A1 (sk)
PL (1) PL214876B1 (sk)
PT (1) PT1392307E (sk)
RS (1) RS50814B (sk)
SI (1) SI1392307T1 (sk)
SK (1) SK287170B6 (sk)
TN (1) TNSN03113A1 (sk)
TW (1) TWI262078B (sk)
UA (1) UA73422C2 (sk)
WO (1) WO2002092089A1 (sk)
ZA (1) ZA200307235B (sk)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286886B6 (sk) * 1997-12-31 2009-07-06 Pfizer Products Inc. Azapolycyklické zlúčeniny s anelovanou arylskupinou, ich použitie, farmaceutické kompozície na ich báze a medziprodukty
KR20040063975A (ko) 2001-11-30 2004-07-15 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]-헥사데카-2(11)3,5,7,9-펜타엔의 약학 조성물
CA2525874C (en) * 2003-05-20 2007-11-27 Pfizer Products Inc. Pharmaceutical compositions of varenicline
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
US20070249623A1 (en) * 2004-06-30 2007-10-25 Eli Lilly And Company Patent Division 1-(Indole-6-Carbonyl-D-Phenylglycinyl)-4-(1-Methylpiperidin-4-Yl)Piperazine D-Tartrate
EP1778669A2 (en) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
DE602005023333D1 (de) * 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
EP1802276A1 (en) * 2004-10-15 2007-07-04 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
CA2598533A1 (en) * 2005-02-24 2006-08-31 Pfizer Products Inc. Preparation of high purity substituted quinoxaline
US20110086086A1 (en) * 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1986994A2 (en) * 2006-02-21 2008-11-05 Teva Pharmaceutical Industries Ltd Novel crystalline forms of armodafinil and preparation thereof
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
KR20090086071A (ko) * 2006-11-09 2009-08-10 화이자 프로덕츠 인코포레이티드 니코틴 중간체의 다형체
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
EP2262780A4 (en) * 2008-03-06 2012-01-25 Reddys Lab Ltd Dr TARTRATE OF VARENICLINE AMORPHOUS
US8440825B2 (en) 2008-03-06 2013-05-14 Medichem S.A. Fumaric acid salt of varenicline
WO2009146031A1 (en) 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
WO2009143347A2 (en) * 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
CA2801842A1 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
RU2012102052A (ru) * 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
WO2011110954A1 (en) 2010-03-09 2011-09-15 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
EP2837632B1 (en) 2012-04-13 2016-05-18 Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases
KR101663550B1 (ko) * 2014-06-11 2016-10-07 조선대학교산학협력단 주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
EP4142734A1 (en) 2020-04-28 2023-03-08 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
WO2021259396A2 (zh) 2021-08-20 2021-12-30 威智医药有限公司 一种亚硝胺杂质、能够减少亚硝胺杂质生成的伐尼克兰药物组合物及其制备与应用
KR20230068877A (ko) 2021-11-11 2023-05-18 주식회사 아울바이오 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물
CN113980020B (zh) * 2021-11-22 2023-05-09 浙江车头制药股份有限公司 一种酒石酸伐尼克兰晶型的制备方法
WO2023275413A2 (en) 2021-12-23 2023-01-05 Medichem, S.A. Solid pharmaceutical formulations of varenicline
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
WO2024095172A1 (en) 2022-11-04 2024-05-10 Pfizer Inc. Prodrugs of varenicline and compounds containing vulnerable amines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
SK286886B6 (sk) * 1997-12-31 2009-07-06 Pfizer Products Inc. Azapolycyklické zlúčeniny s anelovanou arylskupinou, ich použitie, farmaceutické kompozície na ich báze a medziprodukty
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
YU34501A (sh) * 2000-05-26 2003-10-31 Pfizer Products Inc. Postupak reaktivne kristalizacije radi povećanja veličine čestica

Also Published As

Publication number Publication date
TNSN03113A1 (fr) 2005-12-23
HRP20030910A2 (en) 2004-02-29
EG24228A (en) 2008-11-10
UA73422C2 (en) 2005-07-15
CZ304763B6 (cs) 2014-10-01
JP3779682B2 (ja) 2006-05-31
CA2447405A1 (en) 2002-11-21
HU229867B1 (en) 2014-10-28
CZ20032916A3 (cs) 2004-09-15
BR0209605A (pt) 2004-03-23
JP2004533446A (ja) 2004-11-04
ECSP034850A (es) 2003-12-24
IL157933A0 (en) 2004-03-28
DE60205742T2 (de) 2006-05-11
KR20040010638A (ko) 2004-01-31
IS6957A (is) 2003-09-15
EP1392307B1 (en) 2005-08-24
EA200301121A1 (ru) 2004-02-26
OA12599A (en) 2006-06-08
BG108343A (bg) 2004-12-30
ZA200307235B (en) 2004-09-16
AP2002002523A0 (en) 2002-06-30
PA8545101A1 (es) 2003-09-05
ES2246396T3 (es) 2006-02-16
IS2217B (is) 2007-03-15
PL214876B1 (pl) 2013-09-30
US6890927B2 (en) 2005-05-10
GEP20053712B (en) 2005-12-26
SK13362003A3 (en) 2004-11-03
NZ528210A (en) 2005-04-29
PE20021065A1 (es) 2002-11-21
AP1473A (en) 2005-09-30
CA2447405C (en) 2006-10-17
DE60205742D1 (de) 2005-09-29
US20030166701A1 (en) 2003-09-04
HUP0304088A2 (hu) 2004-04-28
NO326148B1 (no) 2008-10-06
ME00466B (me) 2011-10-10
RS50814B (sr) 2010-08-31
TWI262078B (en) 2006-09-21
CN1509174A (zh) 2004-06-30
EE05441B1 (et) 2011-08-15
WO2002092089A1 (en) 2002-11-21
DOP2002000392A (es) 2002-11-15
IL157933A (en) 2013-07-31
NO20035036D0 (no) 2003-11-13
HRP20030910B1 (en) 2011-11-30
SK287170B6 (sk) 2010-02-08
EP1392307A1 (en) 2004-03-03
BG66408B1 (bg) 2014-01-31
MY127807A (en) 2006-12-29
CN100370987C (zh) 2008-02-27
PT1392307E (pt) 2005-11-30
GT200200084A (es) 2003-09-12
AR033635A1 (es) 2003-12-26
US7265119B2 (en) 2007-09-04
CR7080A (es) 2006-08-09
KR100551184B1 (ko) 2006-02-13
MXPA03010364A (es) 2004-03-16
HUP0304088A3 (en) 2011-11-28
HK1062645A1 (en) 2004-11-19
MA27020A1 (fr) 2004-12-20
NO20035036L (no) 2003-11-13
US20050148591A1 (en) 2005-07-07
SI1392307T1 (sl) 2005-12-31
PL366551A1 (en) 2005-02-07
ECSP034849A (es) 2003-12-24
AU2002253482B2 (en) 2007-09-06
EA005528B1 (ru) 2005-04-28
ATE302607T1 (de) 2005-09-15
EE200300556A (et) 2004-04-15
YU86703A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
DK1392307T3 (da) Tartratsalte af 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen
DK1448235T3 (da) Orale, farmaceutiske sammensætninger af 5,8,14-triaza-tetracyclo[10.3.1.0(2,11).0(4.9)]-hexadeca-2(11),3,5,7,9-pentaen med kontrolleret frigivelse
NO20041567L (no) 1,8-nafthyridinderivater som antidiabetiske midler
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
NO20043174L (no) Pyrido[2,1-a]isokinolinderivater som DPP-IV inhibitorer
EE200300557A (et) 5,8,14-triasatetratsüklo [10,3,1,0 2,11 ,0 4,9]heksadeka-2(11),3,5,7,9-pentaeeni tsitraatsool
HK1052703A1 (en) Salts of bicyclic, n-acylated imidazo-3-amines andimidazo-5-amines.
NO20014050D0 (no) 1-aryl-1,3,5-triazin-4-tion-2,6-dioner, fremstilling derav og anvendelse derav som herbicider
NO20034529L (no) 3,7-diazabicyklo(3,3,1) - formuleringer som anti-arytmi- forbindelser
DK1490363T3 (da) Fremgangsmåder til fremstilling af 2-7-chlor-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)1-isoindolinon
ES1049590Y (es) Cenicero ambientador perfeccionado.
ITTO20010077V0 (it) Gruppo vasca per trattamenti di decapaggio.
ES1049575Y (es) Gafa perfeccionada.
DK1289996T3 (da) Heteroaryldiazabicycloalkaner som nicotiniske cholinergiske receptorligander
ES1048649Y (es) Cepillo de dientes perfeccionado.